Treventis Corporation
Treventis Corporation is dedicated to treating and preventing protein misfolding diseases using its proprietary, patented discovery engine – Common Conformational Morphology (CCM). The company focuses on drug discovery for neurodegenerative diseases such as Alzheimer’s, tauopathies, ALS, Parkinson’s, and cancer, leveraging its innovative technology platform to identify druggable active sites in misfolded proteins.
Industries
Nr. of Employees
small (1-50)
Treventis Corporation
1111B South Governors Avenue, Dover, DE 19904
Patents
Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system
US-8795630-B2
View DetailsMethods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
US-8420640-B2
View Details
Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system
US-8795630-B2
View DetailsMethods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
US-8420640-B2
View DetailsProducts
Small-molecule tau and Aβ oligomer inhibitor program (Alzheimer’s and tauopathies)
Preclinical program to discover and optimize small molecules that inhibit tau and Aβ oligomerization using in silico modeling followed by in vitro and in vivo validation; advanced compounds have demonstrated oral bioavailability and in vivo target engagement.
Broad-spectrum TDP oligomer inhibitor program (ALS and TDP-mediated FTD)
Discovery program focused on small molecules that inhibit misfolding/oligomerization of TDP isoforms with the goal of halting aggregate growth and disease progression; multiple chemotypes identified with activity in turbidity and cell-based assays.
p53 oligomer inhibitor program (oncology)
Preclinical discovery of small molecules that inhibit aggregation/oligomerization of mutant p53 with the aim of restoring tumor suppressor function or preventing toxic gain-of-function; initial hits show dose-dependent inhibition and selective activity in mutant p53 cell models.
Small-molecule tau and Aβ oligomer inhibitor program (Alzheimer’s and tauopathies)
Preclinical program to discover and optimize small molecules that inhibit tau and Aβ oligomerization using in silico modeling followed by in vitro and in vivo validation; advanced compounds have demonstrated oral bioavailability and in vivo target engagement.
Broad-spectrum TDP oligomer inhibitor program (ALS and TDP-mediated FTD)
Discovery program focused on small molecules that inhibit misfolding/oligomerization of TDP isoforms with the goal of halting aggregate growth and disease progression; multiple chemotypes identified with activity in turbidity and cell-based assays.
p53 oligomer inhibitor program (oncology)
Preclinical discovery of small molecules that inhibit aggregation/oligomerization of mutant p53 with the aim of restoring tumor suppressor function or preventing toxic gain-of-function; initial hits show dose-dependent inhibition and selective activity in mutant p53 cell models.
Services
Collaborative research, option/license arrangements and partnership-based advancement of preclinical small-molecule programs using an in silico-driven discovery platform; engagement with pharmaceutical partners and government-funded research awards.
Collaborative research, option/license arrangements and partnership-based advancement of preclinical small-molecule programs using an in silico-driven discovery platform; engagement with pharmaceutical partners and government-funded research awards.
Expertise Areas
- Protein misfolding drug discovery
- Small-molecule oligomerization inhibitors
- Neurodegenerative disease preclinical development (Alzheimer’s, ALS, Parkinson’s)
- Oncology-focused small-molecule discovery (mutant p53 aggregation)
Key Technologies
- In silico conformational modeling of misfolded proteins
- Virtual screening and structure-based drug design
- Medicinal chemistry and compound library synthesis
- Surface plasmon resonance (SPR)
News & Updates
April 11, 2023 – Toronto, Ontario, Canada – Treventis Corporation, a privately held biotechnology company, announced today that it has...
October 18, 2022 – Funds for Development of a Drug Against Neurodegenerative Diseases October 18, 2022 BERNVILLE, Pennsylvania – Treventis Corporation, a privately held...
August 5, 2022 – Treventis is pleased to congratulate our founder Dr. Sultan Darvesh, neurologist and Dalhousie professor, for being one of the first...
June 30, 2022 – Treventis founders Donald Weaver and Christopher Barden are both invited speakers at the 12th Triennial Congress of the World Association...
June 8, 2022 – Congratulations to our own Dr. Donald Weaver, Treventis founder and Chief Medical Officer, for being an Oskar Fischer Prize winner!...
April 11, 2023 – Toronto, Ontario, Canada – Treventis Corporation, a privately held biotechnology company, announced today that it has...
April 11, 2023 – Toronto, Ontario, Canada – Treventis Corporation, a privately held biotechnology company, announced today that it has...
October 18, 2022 – Funds for Development of a Drug Against Neurodegenerative Diseases October 18, 2022 BERNVILLE, Pennsylvania – Treventis Corporation, a privately held...
August 5, 2022 – Treventis is pleased to congratulate our founder Dr. Sultan Darvesh, neurologist and Dalhousie professor, for being one of the first...
June 30, 2022 – Treventis founders Donald Weaver and Christopher Barden are both invited speakers at the 12th Triennial Congress of the World Association...
June 8, 2022 – Congratulations to our own Dr. Donald Weaver, Treventis founder and Chief Medical Officer, for being an Oskar Fischer Prize winner!...
April 11, 2023 – Toronto, Ontario, Canada – Treventis Corporation, a privately held biotechnology company, announced today that it has...